PT Kalbe Farma Tbk · IDX:KLBF
PT Kalbe Farma Tbk — FY2021 Earnings Presentation
44 slides from PT Kalbe Farma Tbk's earnings presentation, March 2022
Slide 1: Company Update FY 2021 Audited Results
Company Update FY 2021 Audited Results PT Kalbe Farma Tbk March 2022
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation has been prepared for informational purposes only by PT.Kalbe Farma Tbk. (“Kalbe” or the “Company”). This presentation has been prepared solely for use in connection with the release of 31 December 2021 audited results of the Company. The information conta
Slide 3: Key Updates Business Overview Financial Overview
Key Updates 4 Business Overview 12 Financial Overview 25 Appendix 32
Slide 4: Key Updates
(S KALBE Key Updates THRIVE THROUGH INNOVATION & DIGITALIZATION
Slide 5: FY 2021 Audited Results
FY 2021 Audited Results Growth Challenges Solid top line growth of 13.6% supported by organic volume growth and broad based growth improvement in FY 2021 Volatile economy Strong net income growth of 16.5% that influenced purchasing power Prudent operational efficiency. EPS reached Rp 67.9 as of YTD
Slide 6: Fast Response in Volatile Conditions
Fast Response in Volatile Conditions Diagnostics Vaccine & Curative Products Vaccine Distribution GX-19N vaccine RT-PCR test & RT LAMP method (repurpose the development Fluvir, Covifor, Favikal Reach more than 1000 government for DNA based vaccines) hospitals in 7 provinces . Vitamins/Supplements He
Slide 7: Innovation for Sustainable Growth
Innovation for Sustainable Growth Specialty Insulin monoclonal antibodies (mAbs) & Biosimilar Diagnostic Vaccine Preventive Herbal Vitamins/Supplements Affordable Unbranded Generic Chilgo Powder Herbal Digital
Slide 8: Focus on Customer Needs
Focus on Customer Needs KALBE
Slide 9: Online Digital Solution
Online Digital Solution Telemedicine providing health consultation with doctors and health experts, pharmacy platform and e-commerce for healthcare and wellness products > 14mn users > 465k consultation > 20k doctors Place Your Place Your B2B order management platform for healthcare Place Your Pictu
Slide 10: Strengthening Our Human Capital
Strengthening Our Human Capital KMMP : Kalbe Middle Management Program Health & Mindfulness Meditation KFMP : Kalbe First Line Management Program Leader as Coach Kampus Merdeka Program Kalbe collaborates with the Ministry of Education and Culture, Research and Technology in the Merdeka Indonesia Jay
Slide 11: Access to Healthcare for a Better Life
Access to Healthcare for a Better Life • Increase generic products (>50%), medical devices and diagnostics to support the National Health Insurance scheme • Fight against stunting, supporting nutrition for mothers and children in collaboration with BKKBN (National Family Planning Indonesia) Fast Res
Slide 12: Business Overview
(S KALBE Business Overview THRIVE THROUGH INNOVATION & DIGITALIZATION
Slide 13: Segment & Geographic Breakdown
Segment & Geographic Breakdown • Established in 1966 and headquartered in Jakarta • A public company since 1991 and listed in the Indonesia Stock Exchange – free float stocks (public) 42.08%* • The largest publicly-listed pharmaceuticals company in 5% Southeast Asia – market cap 5.3 billion USD* exp
Slide 14: Prescription Pharmaceuticals Division
Prescription Pharmaceuticals Division 14.8% • No. 1 player in Indonesian prescription pharma market • Performs better than pharma market 5,719 4,984 • Provides access to healthcare through unbranded generic – BPJS program • Expands to specialty products (oncology and biologic) • Creates total health
Slide 15: Prescription Pharmaceuticals Division
Prescription Pharmaceuticals Division Expanding Access to Healthcare - National Health Insurance Program • Selection of focused categories to achieve scale • Dedicated unbranded generic plant Expanding Collaboration in Specialty Category Oncology Products Other Products Biological based Products
Slide 16: Biologics Journey
Biologics Journey Strengthening Presence in Specialty Products • Focus on immuno-oncology products portfolio • Raised USD 105mn from Kalbe, General Atlantic (GA) • Henlius - HLX10 and Genexine in 2021 • IMAB - two molecules • Business expansion through engagement with • Ongoing clinical development
Slide 17: Consumer Health Division
Consumer Health Division +7.1% • No. 1 Player in OTC market and Health Supplement category 3,382 3,623 • Gross Profit Margin YTD 12 2021 is increased to 59.0% from 57.8% in YTD 12 2020, due to products mix. • Strengthening products in vitamin and supplement with the support of scientific information
Slide 18: Consumer Health Division
Consumer Health Division Therapeutic Class Kalbe’s Product Market Share 2020 OTC - Antacids Promag 72% OTC – Anti Diarrhea Neo Entrostop 56% OTC – Cough Remedies Komix, Woods 50% OTC – Cold Remedies Mixagrip, Procold 39% OTC – Children Multivitamin (tablet) Sakatonik ABC 52% Health Supplement Extra
Slide 19: Consumer Health Division
Consumer Health Division ● New products development in 2020 & 2021 are focused on the multivitamin and mineral category Sakatonik Activ D3 1000 IU Xonce 1000 mg Kaplet Komix Herbal for Kids Fatigon Promuno H2 - Cordyceps Femmy D3 1000 IU Femmy Trimune Entrostop Herbal Bejo for Kids Bejo Sujamer ● Co
Slide 20: Herbal Development
Herbal Development Red Ginger & Citronella Building red ginger ecosystem, Kalbe engages with more than 10k farmers across Indonesia Kalbe conducted a lab-scale trial of the clean production red ginger extraction method with both fresh red ginger and dried red ginger, in collaboration with Institut P
Slide 21: Nutritionals Division
Nutritionals Division Strong brand awareness of existing major products 2.5% • Gross Profit Margin YTD 12 2021 declined to 51.5% from 6,994 7,166 53.0% in YTD 12 2020 due to product mix • Offers more affordable products to serve market needs (Zee & Chil Go Powder) • Performs better than powdered mil
Slide 22: Nutritionals Division
Nutritionals Division Catered to expecting & lactating mothers, babies, toddlers, children, teens and adults
Slide 23: Distribution & Logistics Division
Distribution & Logistics Division +25.8% • Managed by PT Enseval Putera Megatrading Tbk (EPMT.JK), a listed subsidiary company (92.47% owned). 9,752 7,752 • Net sales represents the 3rd party product sales and distribution margin of internal product sales for consolidated accounting purposes. • Gros
Slide 24: Distribution & Logistics Division
Distribution & Logistics Division The Most Extensive Distribution Network Medical Devices • Completion of surgical suture production facility to comply with local content regulation • Building own brand “E-Care” for consumables products and “Elvasense” for personal healthcare & diagnostic kit produc
Slide 25: Financial Overview
(S KALBE Financial Overview THRIVE THROUGH INNOVATION & DIGITALIZATION
Slide 26: Consolidated Operational Performance
Consolidated Operational Performance Net Sales (in Rp Bn) +13.6% 31 Dec 2020 31 Dec 2021 (Audited) (Unaudited) 26.261 23,113 +25.8% Growth +14.8% +7.1% +2.5% 9.752 6,994 7,166 7,752 4,984 5,719 3,382 3,623 PRESCRIPTION CONSUMER NUTRITIONALS DISTRIBUTION CONSOLIDATED PHARMACEUTICALS HEALTH & LOGISTIC
Slide 27: Consolidated Operational Performance
Consolidated Operational Performance Gross Profit (in Rp Bn) Operating Expenses to Net Sales Ratio (%) 28.9% 27.7% +10.1% 1.2% 1.1% Research & GPM (%) 44.3% 43.0% 6.0% 5,4% Development General & Administrative 10,246 11.284 21.7% 21,1% Selling Expenses 31 Dec 2020 31 Dec 2021 31 Dec 2020 31 Dec 2021
Slide 28: Consolidated Operational Performance
Consolidated Operational Performance Income Before Tax (in Rp Bn) Net Income (in Rp Bn) +14.2% +16.5% Income before Net Income 15.7% 15.8% Margin (%) 11.8% 12.1% Tax Margin (%) 4.143 3,184 3,628 2,733 31 Dec 2020 31 Dec 2021 31 Dec 2020 31 Dec 2021 (Audited) (Unaudited) (Audited) (Audited) • Positiv
Slide 29: Working Capital Management
Working Capital Management Managing Net Operating Cycle 136 131 126 120 129 Net Operating Cycle has increased from 120 to 129 days 124 122 111 109 101 Improve working capital through building 56 57 54 strong relationship with clients and 51 47 suppliers 38 41 35 40 35 Ensure product availability thr
Slide 30: Capital Allocation
Capital Allocation * All in Rp Billion except for gearing ratio, dividend payout ratio, and dividend yield Total Debt and Gearing Ratio Cash & Net Cash Balance 1,092 817 6,216 5,208 5,633 5.9% 584 4,116 319 357 4.9% 3,153 3,040 2785 2,466 2,796 2,223 2.3% 2.3% 2.7% 2017 2018 2019 2020 2021 2017 2018
Slide 31: Outlook 2022
Outlook 2022 YoY Sales Growth EPS Growth Dividend Payout 11-15% 11-15% Ratio FY21: 16.5% 45-55% FY21: 13.6% • 14,500 USD/IDR exchange rate • 5% - 5.5% Indonesia GDP growth • Capex of Rp 1.0 Tn for production capacity, distribution and network expansion • Share buyback program to strengthen sharehold
Slide 32: Appendix
(S KALBE Appendix THRIVE THROUGH INNOVATION & DIGITALIZATION
Slide 33: Macro Overview
Macro Overview NATIONAL HEALTH INSURANCE (JKN) COVERAGE 2014 133mn people 2015 158mn people 2016 170mn people 2017 188mn people 2018 216mn people 2019 221mn people 2020 222mn people 2021* 230mn people Source : BPJS Kesehatan * As of November 2021 HEALTHCARE ALLOCATION IN 2020 GOVERNMENT BUDGET Handl
Slide 34: Macro Overview
Macro Overview INDONESIA GDP GROWTH GDP GROWTH (%) INFLATION (%) EXCHANGE RATE (Rupiah / USD) The momentum for economic The inflation rate in The rupiah exchange rate in recovery is expected to 2022 is expected to 2022 is expected to be continue in 2022, among strengthen in line maintained in the le
Slide 35: Macro Overview
Macro Overview Recent Pharma Regulations : Government Regulation No. 45 Year 2019 • Super deduction of R&D cost (PMK 153 year 2020) and vocational training cost (PMK 128 year 2019) which will lower the tax base for corporate income tax calculation. Perppu No. 1 Year 2020 • Regarding the reduction of
Slide 36: ESG Achievements and Activities
ESG Achievements and Activities SUSTAINABILITY REPORT KALBE Bisnis Indonesia CSR Award 2021 Kalbe has started Sustainability Report “Platinum Champion since 2017, prepared based on the Global In Corporate Social Reporting Initiatives (GRI) guidelines Responsibility https://www.kalbe.co.id/investor/f
Slide 37: Appendix
(S KALBE Appendix 2 THRIVE THROUGH INNOVATION & DIGITALIZATION
Slide 38: Consolidated Statement of Financial Position
CONSOLIDATED STATEMENT OF FINANCIAL POSITION Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change ASSETS CURRENT ASSETS Cash and Cash Equivalents 6.216.247.801.928 5.207.929.420.504 19,4% Trade Receivables 3.431.018.099.213 3.477.220.762.616 -1,3% Other Receivables 114.124.556.39
Slide 39: Consolidated Statement of Financial Position
CONSOLIDATED STATEMENT OF FINANCIAL POSITION Expressed in Rupiah 31 Dec 2021 31 Dec 2020 % Change (Audited) (Audited) LIABILITIES CURRENT LIABILITIES Short-term Bank Loans - 220.500.000.000 -100,0% Trade Payables 1.667.595.790.804 1.240.385.598.118 34,4% Other Payables 710.888.106.011 656.249.988.65
Slide 40: Consolidated Statement of Profit or Loss and Other Comprehensive Income
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change NET SALES 26.261.194.512.313 23.112.654.991.224 13,6% COST OF GOODS SOLD 14.977.410.271.049 12.866.332.497.453 16,4% % to NS 55,6% 55,7% GROSS PROFIT 11.28
Slide 41: Consolidated Statement of Profit or Loss and Other Comprehensive Income
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change INCOME TAX EXPENSE, NET (911.256.951.493) (828.010.058.930) 10,1% % to NS -3,7% -3,6% INCOME FOR THE YEAR 3.232.007.683.281 2.799.622.515.814 15,4% % to NS
Slide 42: Consolidated Statement of Cash Flows
CONSOLIDATED STATEMENT OF CASH FLOWS Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change CASH FLOWS FROM OPERATING ACTIVITIES Cash Received from Customers 28.936.595.007.408 25.453.548.262.874 13,7% Cash Payments to Suppliers and Employees (18.765.991.549.730) (15.295.694.265.14
Slide 43: Consolidated Statement of Cash Flows
CONSOLIDATED STATEMENT OF CASH FLOWS Expressed in Rupiah 31 Dec 2021 31 Dec 2020 (Audited) (Audited) % Change CASH FLOWS FROM FINANCING ACTIVITIES Receipt of Capital Contributions from Subsidiary’s Non-controlling Interests 1.227.271.550.000 - 100,0% Proceeds from Short-term Bank Loans 136.100.000.0
Slide 44: Thank You
THRIVE THROUGH INNOVATION & DIGITALIZATION KALBE™ ges - |: